Ushbu ish iqtibos qilgan ishlar

262 ta ish

Ish: Tumor Microenvironment‐Responsive Nanomedicines for Potentiating Cancer Immunotherapy

Targeted nanomedicines remodeling immunosuppressive tumor microenvironment for enhanced cancer immunotherapy
Yanyan Xu, Jingyuan Xiong, Xiyang Sun +1
Sharh maqola20222 iqtibos
ABI
Towards precision medicine using biochemically triggered cleavable conjugation
Badri Parshad, Smriti Arora, Balram Singh +4
Sharh maqola20252 iqtibos
ABI
Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?
Dunyaporn Trachootham, Jérôme Alexandre, Peng Huang
Sharh maqola20092 iqtibos
ABI
T cell exclusion, immune privilege, and the tumor microenvironment
Johanna A. Joyce, Douglas T. Fearon
Sharh maqola20152 iqtibos
ABI
Enzyme-responsive nanomaterials for controlled drug delivery
Quanyin Hu, Prateek S. Katti, Zhen Gu
Sharh maqola20142 iqtibos
ABI
Analysis of nanoparticle delivery to tumours
Stefan Wilhelm, Anthony J. Tavares, Qin Dai +4
Sharh maqola20162 iqtibos
ABI
Reactive‐Oxygen‐Species‐Responsive Drug Delivery Systems: Promises and Challenges
Gurusamy Saravanakumar, Jihoon Kim, Won Jong Kim
Sharh maqola20162 iqtibos
ABI
Elements of cancer immunity and the cancer–immune set point
Daniel S. Chen, Ira Mellman
Sharh maqola20172 iqtibos
ABI
Nanoparticles for modulating tumor microenvironment to improve drug delivery and tumor therapy
Shu Yang, Huile Gao
Sharh maqola20172 iqtibos
ABI
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le, Jennifer N. Durham, Kellie N. Smith +43
Maqola20172 iqtibos
ABI
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Sanjeev Mariathasan, Shannon J. Turley, Dorothee Nickles +39
Maqola20182 iqtibos
ABI
Defining ‘T cell exhaustion’
Christian U. Blank, W. Nicholas Haining, Werner Held +15
Sharh maqola20192 iqtibos
ABI
The dose threshold for nanoparticle tumour delivery
Ben Ouyang, Wilson Poon, Yi-Nan Zhang +11
Maqola20202 iqtibos
ABI
Applying high-dimensional single-cell technologies to the analysis of cancer immunotherapy
Satyen H. Gohil, J. Bryan Iorgulescu, David A. Braun +2
Sharh maqola20202 iqtibos
ABI
Off-the-Shelf Chimeric Antigen Receptor T Cells
Norihiro Watanabe, Maksim Mamonkin
Sharh maqola20212 iqtibos
ABI
Anti-angiogenic agents — overcoming tumour endothelial cell anergy and improving immunotherapy outcomes
Zowi R. Huinen, Elisabeth J. M. Huijbers, Judy R. van Beijnum +2
Sharh maqola20212 iqtibos
ABI
Modulation of the tumor micro-environment by CD8+ T cell-derived cytokines
Mirjam E. Hoekstra, Saskia V Vijver, Ton N. Schumacher
Sharh maqola20212 iqtibos
ABI
In Situ Tumor Vaccination with Nanoparticle Co‐Delivering CpG and STAT3 siRNA to Effectively Induce Whole‐Body Antitumor Immune Response
Worapol Ngamcherdtrakul, Moataz Reda, Molly A. Nelson +11
Maqola20212 iqtibos
ABI
Hypoxia and the Tumor Microenvironment
Yue Li, Long Zhao, Xiaofeng Li
Sharh maqola20212 iqtibos
ABI
Microenvironment‐Responsive Prodrug‐Induced Pyroptosis Boosts Cancer Immunotherapy
Yao Xiao, Tian Zhang, Xianbin Ma +6
Maqola20212 iqtibos
ABI
Desmoplastic Reaction, Immune Cell Response, and Prognosis in Colorectal Cancer
Naohiko Akimoto, Juha P. Väyrynen, Melissa Zhao +18
Maqola20222 iqtibos
ABI
NIR/pH-responsive chitosan hydrogels containing Ti3C2/AuNRs with NIR-triggered photothermal effect
Chongchong Liu, Panping Yang, Jingguo Li +2
Maqola20222 iqtibos
ABI
Reactive oxygen species-responsive polymer drug delivery systems
Jiaxue Liu, Boyan Jia, Zhibo Li +1
Sharh maqola20232 iqtibos
ABI
<scp>pH</scp>‐responsive polymers for drug delivery: Trends and opportunities
Jagtar Singh, Pallavi Nayak
Maqola20232 iqtibos
ABI
The cancer-immunity cycle: Indication, genotype, and immunotype
Ira Mellman, Daniel S. Chen, Thomas Powles +1
Sharh maqola20232 iqtibos
ABI